The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation

Transplantation

Volumn 90, Issue 12, 2010, Pages 1486-1492

  Flechner, Stuart M ^a   Fatica, Richard ^a   Askar, Medhat ^a   Stephany, Brian R ^a   Poggio, Emilio ^a   Koo, Anna ^a   Banning, Stacey ^a   Chiesa Vottero, Andres ^a   Srinivas, Titte ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Alloantibody; Antibody mediated rejection; Bortezomib; Complement

Indexed keywords

BORTEZOMIB; COMPLEMENT COMPONENT C4D; CORTICOSTEROID; CREATININE; CYCLOSPORIN A; FLUOROCHROME; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; PROTEIN; RAPAMYCIN; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; AGED; ANTIBODY MEDIATED REJECTION; ARTICLE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DRUG TOLERABILITY; FATIGUE; FEMALE; FLUID RETENTION; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; GRAFT SURVIVAL; HISTOLOGY; HUMAN; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; RETREATMENT; SIDE EFFECT; THROMBOCYTOPENIA;

ACTUARIAL ANALYSIS; ADRENAL CORTEX HORMONES; ADULT; AGED; ANTIBODY SPECIFICITY; BORONIC ACIDS; COMBINED MODALITY THERAPY; CREATININE; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PANCREAS TRANSPLANTATION; PLASMAPHERESIS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES;

EID: 78650840827     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181fdd9b0     Document Type: Article

References (18)

1. Terasaki P, Ozawa M. Predictive value of HLA antibodies and serum creatinine in chronic rejection: Results of a 2-year prospective trial. Transplantation 2005; 80: 1194.
2. Hourmant M, Cesbron-Gautier A, Terasaki P, et al. Frequency and clinical implications of development of donor-specific and non- donor-specific HLA antibodies after kidney transplantation. J Am Soc Nephrol 2005; 16: 2804.
3. Colvin RB. Antibody-mediated renal allograft rejection: Diagnosis and pathogenesis. J Am Soc Nephrol 2007; 18: 1046.
4. Ramos EJ, Pollinger HS, Stegall MD, et al. The effect of desensitization protocols on human splenic B-cell populations in vivo. Am J Transplant 2007; 7: 402.
5. Perry DK, Pollinger HS, Burns JM, et al. Two novel assays of alloantibody-secreting cells demonstrating resistance to desensitization with IVIG and rATG. Am J Transplant 2008; 8: 133.
6. Cascio P, Oliva L, Cerruti F, et al. Dampening Ab responses using proteasome inhibitors following in vivo B cell activation. Eur J Immunol 2008; 38: 658.
7. Perry DK, Burns JM, Pollinger HS, et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 2009; 9: 201.
8. Everly MJ, Everly J, Susskind B, et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 2008; 86: 1754.
9. Sberro-Soussan R, Zuber J, Suberbielle-Boissel C, et al. Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies. Am J Transplant 2010; 10: 681.
10. Solez K, Colvin RB, Racusen LC, et al. Banff '07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008; 8: 753.
11. Stegall MD, Gloor JM. Deciphering antibody-mediated rejection: New insights into mechanisms and treatment. Curr Opin Organ Transpl 2010; 15: 8.
12. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. NEJM 2003; 348: 2609.
13. Cosio FG, Gloor JM, Sethi S, et al. Transplant Glomerulopathy. Am J Transplant 2008; 8: 492.
14. Issa N, Cosio FG, Gloor JM, et al. Transplant glomerulopathy: Risk and prognosis related to anti-human leukocyte antigen class II antibody levels. Transplantation 2008; 86: 681.
15. Homsa S, Mansoura H, Desvauxa D, et al. Predominant Th1 and cytotoxic phenotype in biopsies from renal transplant recipients with transplant glomerulopathy. Am J Transplant 2009; 9: 1230.
16. Yanaba K, Yoshizaki A, Muroi E, et al. The proteasome inhibitor bortezomib inhibits T cell-dependent inflammatory responses. J Leukoc Biol 2010; 88: 117.
17. Fernández-Fresnedo G, Plaza JJ, Sánchez-Plumed J, et al. Proteinuria: A new marker of long-term graft and patient survival in kidney transplantation. Nephrol Dial Transplant 2004; 19(suppl 3): 47.
18. Halimi JM, Laouada I, Buchler M, et al. Early low-grade proteinuria: Causes, short-term evolution and long-term consequences in renal transplantation. Am J Transplant 2005; 5: 2281.